NEWS

Company news and the latest scientific findings

|

May 2024

ME Therapeutics Holdings Inc. (METX:CSE), a preclinical stage biotechnology company working on novel cancer fighting drugs in the field of Immuno-Oncology,

|

Apr 2024

ME Therapeutics Holdings Inc. (METX:CSE), a preclinical stage biotechnology company working on novel cancer fighting drugs in the field of Immuno-Oncology,

|

Apr 2024

ME Therapeutics Holdings Inc. (METX:CSE), a preclinical stage biotechnology company working on novel cancer fighting drugs in the field of Immuno-Oncology,

|

Mar 2024

ME Therapeutics Holdings Inc. (METX:CSE), a preclinical stage biotechnology company working on novel cancer fighting drugs in the field of Immuno-Oncology,

|

Jan 2024

ME Therapeutics Holdings Inc. (METX:CSE), a preclinical stage biotechnology company working on novel cancer fighting drugs in the field of Immuno-Oncology,

|

Dec 2023

ME Therapeutics Holdings Inc. (METX:CSE), a preclinical stage biotechnology company working on novel cancer fighting drugs in the field of Immuno-Oncology,

|

Dec 2023

ME Therapeutics Holdings Inc. (METX:CSE), a preclinical stage biotechnology company working on novel cancer fighting drugs in the field of Immuno-Oncology,

|

Oct 2023

ME Therapeutics Holdings Inc. (CSE: METX) (the “Company” or “MET”), a preclinical stage biotechnology company working on novel cancer fighting drugs

|

Oct 2023

ME Therapeutics Holdings Inc. (CSE: METX) (the “Company” or “MET”), a preclinical stage biotechnology company working on novel cancer fighting drugs

|

Mar 2023

ME Therapeutics Inc., a preclinical stage biotechnology company working on novel cancer fighting drugs in the field of Immuno-Oncology, is pleased

Check out our profile on SEDAR+

Search

Keep up to date by subscribing to our mailing list